Andere talen Prescient Therapeutics Limited

Aandelen

PTX

AU000000PTX3

Beurs gesloten - Australian S.E. Andere beurzen 08:10:13 28-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,038 ^AUD	-2,56%		-6,17%	-38,71%

25/03	Transcript : Prescient Therapeutics Limited - Special Call
23/02	Prescient Therapeutics Limited rapporteert winstresultaten voor het halfjaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Prescient Therapeutics PTX-100 shows promising results in Phase 1b study	22/05
Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	23/02
Prescient Therapeutics Receives AU$2.4 Million R&D Tax Rebate; Shares Down 4%	28/11
Prescient Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	25-08-23
Prescient Therapeutics showcases cell therapy data at prestigious ISCT conference	16-06-23
Prescient Therapeutics Limited Appoints Ellen Feigal to the Board as Non- Executive Director	15-05-23
Prescient Therapeutics Limited Provides an Update on the PTX-100 Phase 1b Expansion Cohort in Relapsed and Refractory T Cell Lymphomas	15-03-23
Prescient Therapeutics thrilled with additional Orphan Drug Designation status for PTX-100	09-03-23
Prescient Therapeutics Secures US FDA Orphan Drug Designation for Lymphoma Medication; Shares Surge 29%	09-03-23
Prescient Therapeutics Announces FDA Grants Broader Orphan Drug Status to PTX-100 for TCL Indications	08-03-23
Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	24-02-23
Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	24-02-23
Prescient Therapeutics Sees Positive Results in PTX-100 Study	26-10-22
Prescient Therapeutics Limited Announces PTX-100 Trial Update	25-10-22
Prescient Therapeutics Unveils Cancer Drug CellPryme-A; Shares Rise 3%	23-09-22
Prescient Therapeutics Unveils CellPryme-A to Boost Car-T Performance	23-09-22
Prescient Therapeutics, MD Anderson Cancer Center to Develop Blood Cancer Binder for OmniCAR; Shares Rise 3%	07-09-22
Prescient Therapeutics Announces a Strategic Collaboration with the Larger Cancer Centre in the US1, the University of Texas MD Anderson Cancer Center	07-09-22
Prescient Therapeutics Launches $6 Million Share Purchase Plan	24-08-22
Prescient Therapeutics Limited Signs Agreement with Thermo Fisher Scientific to Accelerate OmniCAR Platform Development	18-08-22

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Prescient Therapeutics Limited

Aandelen

PTX

AU000000PTX3

Andere talen

Filters